We are live on ! Find out more
FTH

Faeth Therapeutics
FTH

42 hedge funds and large institutions have $8.21M invested in Faeth Therapeutics in 2022 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 9 increasing their positions, 15 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

83% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 6

14% more funds holding

Funds holding: 37 → 42 (+5)

0.02% more ownership

Funds ownership: 0.56% → 0.58% (+0.02%)

40% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 15

58% less capital invested

Capital invested by funds: $19.7M → $8.21M (-$11.5M)

Holders
42
Holders Change
+5
Holders Change %
+13.51%
% of All Funds
0.66%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
9
Reduced
15
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$331K
2
HighTower Advisors
HighTower Advisors
Illinois
+$200K
3
BCM
Bridgeway Capital Management
Texas
+$151K
4
Two Sigma Investments
Two Sigma Investments
New York
+$133K
5
Bank of America
Bank of America
North Carolina
+$91.4K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$149K
2
BlackRock
BlackRock
New York
-$138K
3
Morgan Stanley
Morgan Stanley
New York
-$102K
4
VF
Virtu Financial
New York
-$93K
5
CSS
Cubist Systematic Strategies
Connecticut
-$74K
Name Holding Trade Value Shares
Change 		Change in
Stake
Jane Street
26
Jane Street
New York
$25K +$42.8K +538 New
AIG
27
American International Group
New York
$24K -$2.87K -36 -6%
California State Teachers Retirement System (CalSTRS)
28
California State Teachers Retirement System (CalSTRS)
California
$21K -$8.75K -110 -19%
Wells Fargo
29
Wells Fargo
California
$16K -$7.08K -89 -20%
New York State Common Retirement Fund
30
New York State Common Retirement Fund
New York
$13K – – –
TRCT
31
Tower Research Capital (TRC)
New York
$11K +$4.54K +57 +31%
BCV
32
Banque Cantonale Vaudoise
Switzerland
$9K +$11.9K +150 +333%
Barclays
33
Barclays
United Kingdom
$8K +$13.5K +170 New
FIA
34
FNY Investment Advisers
New York
$8K +$13.9K +175 New
AB
35
Amalgamated Bank
New York
$6K +$10K +126 New
AF
36
Amalgamated Financial
New York
$6K +$10K +126 New
Citigroup
37
Citigroup
New York
$5K -$17.1K -215 -67%
AIP
38
Ameritas Investment Partners
Nebraska
$4K – – –
Legal & General Group
39
Legal & General Group
United Kingdom
$4K – – –
Royal Bank of Canada
40
Royal Bank of Canada
Ontario, Canada
$3K -$12.2K -153 -71%
VF
41
Virtu Financial
New York
– -$93K -799 Closed
CSS
42
Cubist Systematic Strategies
Connecticut
– -$74K -640 Closed
JF
43
Jump Financial
Illinois
– -$68K -590 Closed
IRAG
44
Investment Research & Advisory Group
Georgia
– -$4K -70 Closed
PHK
45
Point72 Hong Kong
Hong Kong
– -$4K -39 Closed
SCA
46
Snowden Capital Advisors
New York
– -$1K -10 Closed
Fidelity Investments
47
Fidelity Investments
Massachusetts
– +$716 +9 New
1
2

FTH Hedge Fund Activity: Q1 2022 in Review

42 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Faeth Therapeutics (FTH) for Q1 2022, worth a combined $8.21M — down 58% from $19.7M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new FTH positions and 6 closed out — a net gain of 5 holders — while 9 added to existing stakes and 15 trimmed.

The largest buyer was Renaissance Technologies, opening a new position worth an estimated $331K. The largest seller was Millennium Management, cutting an estimated $149K.

  • 42 institutional investors held Faeth Therapeutics (FTH) as of Q1 2022, up from 37 in Q4 2021.
  • Funds reported $8.21M of Faeth Therapeutics stock for Q1 2022, down 58% quarter-over-quarter.
  • 11 funds opened new Faeth Therapeutics positions in Q1 2022 and 6 closed out, a net change of +5 holders.
  • The largest Faeth Therapeutics buyer in Q1 2022 was Renaissance Technologies, an estimated $331K added.
  • The largest Faeth Therapeutics seller in Q1 2022 was Millennium Management, an estimated $149K sold.

Based on aggregated 13F filings for Q1 2022.